SCHEMBL30239158

SCHEMBL30239158

CCOC(=O)c1cn(CCNC(=O)OC(C)(C)C)nc1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
CA12 O43570 1/20 0.46
CA9 Q16790 1/20 0.46
TEAD2 Q15562 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CKS1B P61024 2/20 0.44
SKP1 P63208 2/20 0.44
SKP2 Q13309 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
BTK Q06187 1/20 0.43
ADORA3 P0DMS8 2/20 0.42
ADORA2A P29274 1/20 0.42
IDO1 P14902 1/20 0.42
MAPT P10636 2/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15472754 0.93 BTK (0.54) MAPK1NPSR1CA12CA9TEAD2
SCHEMBL24930987 0.88 CKS1B (0.47) CKS1BSKP1SKP2KMT2ABTK
SCHEMBL24931118 0.84 CRHBP (0.45) NPC1RAB9AADORA3ADORA2AIDO1
SCHEMBL31518572 0.82 ADORA3 (0.43) NPSR1TEAD2ADORA3ADORA2AMAPT
SCHEMBL18764872 0.80 ADORA3 (0.40) NPSR1ADORA3ADORA2AIDO1MAPT
SCHEMBL20027638 0.79 MAPK1 (0.60) MAPK1NPSR1CA12CA9TEAD2
SCHEMBL30239555 0.78 JAK2 (0.41) NPSR1MEN1KMT2AADORA3ADORA2A
SCHEMBL31518447 0.78 ADORA3 (0.39) MAPK1NPSR1CA12CA9ADORA3
SCHEMBL10988922 0.76 MAPK1 (0.63) MAPK1NPSR1CA12CA9TEAD2
SCHEMBL30872245 0.76 ADORA3 (0.41) NPSR1KMT2AADORA3ADORA2AIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. 2024-11-14 US disclosed
CN-118401507-A Inhibitors targeting ubiquitin-specific protease 7 (USP 7) 丹娜法伯癌症研究院 2024-07-26 CN disclosed
EP-4373816-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) Dana-Farber Cancer Institute, Inc. (US) 2024-05-29 EP disclosed
WO-2023003973-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) USP7, USP47, USP2 MAPK1 2721/4885NPSR1 3123/4885CA12 3109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.